|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-2.09/-1.64
|
Enterprise Value
583.44M
|
Balance Sheet |
Book Value Per Share
3.00
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
95.00K
|
Operating Revenue Per Share
0.00
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/05/14 17:47 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research anddevelopment efforts. |